Collaborative Arrangements (Tables)

12 Months Ended

Dec. 31, 2017

Collaborative Arrangements [Abstract]

Schedule of Collaborative Arrangements and Non-collaborative Arrangement Transactions

Summarized information related to this collaboration is as follows:

Year Ended December 31	2017
Alliance revenues (net of commercialization costs)	$	20
Materials and production costs	4
Marketing and administrative expenses	1
Research and development expenses	2,419
Receivables from AstraZeneca	12
Payables to AstraZeneca	643

Expenses do not include all amounts attributed to activities related to the collaboration, rather only the amounts relating to payments between partners. Amounts in materials and production costs include amortization of related intangible assets.

Summarized information related to this collaboration is as follows:

Years Ended December 31	2017		2016		2015
Net product sales recorded by Merck	$	149	$	88	$	—
Merck’s profit share of sales in Bayer's marketing territories	151		81		30
Total sales	300		169		30
Materials and production costs	99		133		67
Marketing and administrative expenses	27		26		3
Research and development expenses	96		45		3
Receivables from Bayer	33		—
Payables to Bayer	352		353